Piramal Pharma Limited Converts the Coal-Fired Steamer at its Digwal Facility to Operate on Biomass Briquettes, Advancing Decarbonization Efforts ...

On 14 November, Eli Lilly became a part of this group, after an account using its name and logo sent out ... the creation of a major new genome project. Pharma giant AbbVie has been taken to ...

Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...

AbbVie (ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, announced an option to license agreement to develop SIM0500, ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

By Sneha S K and Christy Santhosh (Reuters) -AbbVie plans to "commit less capital" towards experimental medicines for ...

In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer ...

Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer ...

It's encouraging to see that AbbVie has been growing its earnings per share at 5.7% a year over the past five years. While EPS is growing at a decent rate, but future growth could be limited by ...

In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 ...

AbbVie, with a market cap of over $300 billion ... The company has continued to find new indications for Botox and the company's Vraylar has crossed $3 billion in peak sales with indications ...

AbbVie will write off $3.5 billion related to its $8.7 billion investment in Cerevel Therapeutics following the failure of the company's key schizophrenia drug, emraclidine, The Wall Street ...